These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36518248)

  • 1. Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC.
    Tang Y; Li J; Liu B; Ran J; Hu ZY; Ouyang Q
    Front Endocrinol (Lausanne); 2022; 13():1075830. PubMed ID: 36518248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
    Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
    EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
    Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
    JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
    Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
    J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis.
    Gerratana L; Davis AA; Velimirovic M; Clifton K; Hensing WL; Shah AN; Dai CS; Reduzzi C; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Puglisi F; Ma CX; Bardia A; Cristofanilli M
    Breast Cancer Res; 2023 Oct; 25(1):112. PubMed ID: 37784176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
    Bardia A; Su F; Solovieff N; Im SA; Sohn J; Lee KS; Campos-Gomez S; Jung KH; Colleoni M; Vázquez RV; Franke F; Hurvitz S; Harbeck N; Chow L; Taran T; Rodriguez Lorenc K; Babbar N; Tripathy D; Lu YS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34504990
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tang Y; Li J; Xie N; Yang X; Liu L; Wu H; Tian C; He Y; Wang X; He Q; Hu ZY; Ouyang Q
    Aging (Albany NY); 2020 Jan; 12(2):1577-1590. PubMed ID: 31980592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial.
    Chiu J; Su F; Joshi M; Masuda N; Ishikawa T; Aruga T; Zarate JP; Babbar N; Balbin OA; Yap YS
    BMC Med; 2023 Aug; 21(1):306. PubMed ID: 37580773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
    Hensing WL; Gerratana L; Clifton K; Medford AJ; Velimirovic M; Shah AN; D'Amico P; Reduzzi C; Zhang Q; Dai CS; Denault EN; Bagegni NA; Opyrchal M; Ademuyiwa FO; Bose R; Behdad A; Ma CX; Bardia A; Cristofanilli M; Davis AA
    Clin Cancer Res; 2023 Aug; 29(16):3092-3100. PubMed ID: 37265453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
    Tolaney SM; Toi M; Neven P; Sohn J; Grischke EM; Llombart-Cussac A; Soliman H; Wang H; Wijayawardana S; Jansen VM; Litchfield LM; Sledge GW
    Clin Cancer Res; 2022 Apr; 28(8):1500-1506. PubMed ID: 35121623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.
    Fuentes-Antrás J; Martínez-Rodríguez A; Guevara-Hoyer K; López-Cade I; Lorca V; Pascual A; de Luna A; Ramírez-Ruda C; Swindell J; Flores P; Lluch A; Cescon DW; Pérez-Segura P; Ocaña A; Jones F; Moreno F; García-Barberán V; García-Sáenz JÁ
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
    Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
    Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
    Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.
    Jacob S; Davis AA; Gerratana L; Velimirovic M; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Bardia A; Cristofanilli M
    Clin Cancer Res; 2021 Mar; 27(5):1361-1370. PubMed ID: 33323406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease.
    Page K; Martinson LJ; Fernandez-Garcia D; Hills A; Gleason KLT; Gray MC; Rushton AJ; Nteliopoulos G; Hastings RK; Goddard K; Ions C; Parmar V; Primrose L; Openshaw MR; Guttery DS; Palmieri C; Ali S; Stebbing J; Coombes RC; Shaw JA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34849446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.